← back to search

Saswati Hazra

Exelixis (United States) · US
Area of research
Pharmacology · Epidemiology
Research interest
Research interests include Inflammatory mediators and NSAID effects, Liver Disease Diagnosis and Treatment, Peroxisome Proliferator-Activated Receptors, and MicroRNA in disease regulation.
h-index
22
citations
2,654
works
64
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology 2022cited by 514position: middledoi
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer
Science Translational Medicine 2013cited by 347position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Phillip Kim · Forest Institute1 papers (2013–2013)Ivan Borbath · Buildwise1 papers (2022–2022)Maurizio Scaltriti · AstraZeneca (Japan)1 papers (2013–2013)Fawzi Benzaghou · Ipsen (France)1 papers (2022–2022)José Baselga · Vall d'Hebron Institute of Oncology1 papers (2013–2013)Philippe Merle · Université Claude Bernard Lyon 11 papers (2022–2022)Kamalika Banerjee · Axcella Health (United States)1 papers (2022–2022)Ana Bosch Campos · Lund University1 papers (2013–2013)В. В. Бредер · Russian Cancer Research Center NN Blokhin1 papers (2022–2022)Ann‐Lii Cheng · Xi'an Jiaotong University1 papers (2022–2022)Robin Kate Kelley · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2022–2022)Moshe Elkabets · Center for Cancer Research1 papers (2013–2013)Jordi Rodón · University of California San Francisco Medical Center1 papers (2013–2013)Cornelia Quadt · Novartis (Switzerland)1 papers (2013–2013)Gontran Verset · Université Libre de Bruxelles1 papers (2022–2022)Andrew X. Zhu · University of Oxford1 papers (2022–2022)— · 1 papers (2013–2013)Jeffrey A. Engelman · Novartis (Germany)1 papers (2013–2013)Alan Huang · Novartis (Switzerland)1 papers (2013–2013)Tamar Melkadze · Institute of Clinical Research1 papers (2022–2022)